BOSTON, June 4, 2024 /PRNewswire/ — Keragon, an AI-powered HIPAA-compliant automation platform for healthcare, is officially launching out of stealth. It is the first no-code workflow automation platform designed specifically for the US healthcare industry. Currently, it is used by practices and clinics, fast-growing digital health startups, all the way up to hospitals & NASDAQ-listed companies, across the 50 states.
The platform enables instant integration of various popular software used by healthcare practitioners (such as EHRs, healthcare CRMs, AI medical scribes, appointment scheduling & billing software). It has also built-in personalized AI assistants that fuel faster automations with less hassle.
Keragon empowers healthcare professionals without a technical background to create powerful automations that can save significant operational costs, improve clinical efficiency and ultimately improve patient care and reduce physician burnout. With over 100 pre-built healthcare integrations, multiple data transformation helpers and advanced error debugging capabilities, it is set to accelerate the digital transformation of healthcare.
Typical use cases include:
Keragon is on a mission to improve healthcare’s operational efficiency, while promoting the use of security best practices for all software vendors that handle sensitive patient data. It has been certified as both SOC 2 Type 2 & HIPAA compliant from external auditors.
The pre-seed funding round was co-led by Focal and Afore, followed by 25 Madison Health – Lifepoint Health.
About Keragon
Keragon is a no-code automation platform designed specifically for the healthcare industry. It allows healthcare professionals to easily connect all their healthcare software solutions, both homegrown and third-party, and build HIPAA-compliant workflows and automations without coding. The Keragon platform has over 100 pre-built integrations with leading healthcare apps, featuring capabilities like patient onboarding, triage, messaging, lab ordering, and appointment scheduling, as well as approval processes and data syncing across systems.
Contact: press@keragonhq.com
SOURCE Keragon
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…